Determination of critical concentrations of moxifloxacin and gatifloxacin for drug susceptibility testing of Mycobacterium tuberculosis in the BACTEC MGIT 960 system

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 10, 2013, Pages 2274-2281

  Isaeva, Yu ^a   Bukatina, A ^a   Krylova, L ^a   Nosova, E ^a   Makarova, M ^a   Moroz, A ^a  

^a Moscow Department of Health   (Russian Federation)

Author keywords

Drug resistance; Fluoroquinolones; Microbiology; Rapid tuberculosis diagnostics

Indexed keywords

GATIFLOXACIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE;

ARTICLE; BACTERIAL STRAIN; DRUG SENSITIVITY; GENE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

DRUG RESISTANCE; FLUOROQUINOLONES; MICROBIOLOGY; RAPID TUBERCULOSIS DIAGNOSTICS;

ANTITUBERCULAR AGENTS; AUTOMATION, LABORATORY; AZA COMPOUNDS; CULTURE MEDIA; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES;

EID: 84888798708     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt202     Document Type: Article

References (24)

1. World Health Organization. Global Tuberculosis Control 2011. http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf (18 January 2013, date last accessed).
2. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52: 1-77.
3. Borisov SE, Mohireva LV, Ivanushkina TN et al. Fluoroquinolones in the treatment of tuberculosis2in search of a new paradigm (review of foreign literature). Tuberc Lung Dis 2011; 12: 5-16 (in Russian).
4. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3: 432-42.
5. Low D.E. Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective. Clin Infect Dis 2009; 48: 1361-3.
6. Moadebi S, Harder C, Fitzgerald M et al. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007; 67: 2077-99.
7. Richeldi L, Covi M, Ferrara G et al. Clinical use of levofloxacin in the long-term treatment of drug resistant tuberculosis. Monaldi Arch Chest Dis 2002; 57: 39-43.
8. Yew WW, Chan CK, Leung CC et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003; 124: 1476-81.
9. Alvirez-Freites EJ, Carter JL, Cynamon M.H. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 1022-5.
10. Bryskier A, Lowther J. Fluoroquinolones and tuberculosis. Expert Opin Investig Drugs 2002; 11: 233-58.
11. Johnson J, Hadad D, Boom W et al. Earlyand extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10: 605-12.
12. Rodriguez JC, Ruiz M, Lopez M et al. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002; 20: 464-7.
13. Dorozhkova IR, Freiman GE, Abramova ZP et al. New technology to screen for pulmonary T.B. Rus Med J 2007; 2: 12-5 (in Russian).
14. Canetti G, Froman S, Grosset J et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull WHO 1963; 29: 565-78.
15. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes-Second Edition: Approved Standard M24-A2. CLSI,Wayne, PA, USA, 2011.
16. Kheifets L.B. Microbiological aspects of identification of patients with drug-resistant tuberculosis. Probl Tuberk Bolezn Legk 2004; 5: 3-6.
17. Krüüner A, Yates MD, Drobniewski F.A. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentration of firstand second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 811-8.
18. World Health Organization. Policy Guidance on Drug-susceptibility Testing (DST) of Second-line Antituberculosis Drugs. http://www.who.int/tb/publications/2008/who_htm_tb_2008_392.pdf (18 January 2013, date last accessed).
19. Van Ingen J, Simons S, Zwaande R et al. Comparative studyongenotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010; 48: 2749-53.
20. Ministry of Health of the Russian Federation. Order 'On Improvement of Tuberculosis-Controlling Measures in the Russian Federation' under No. 109 on 21 March 2003. http://48rospotrebnadzor.ru/files.aspx?id=1bf0f4ed590545f3b2921079c2669ba8 (in Russian) (18 January 2013, date last accessed).
21. Becton Dickinson. 2002. BACTEC MGIT 960 SIRE Kit for the Antimycobacterial Susceptibility Testing of Mycobacterium tuberculosis. http://www.bd.com/ds/technicalCenter/clsi/clsi-960sire.pdf (18 January 2013, date last accessed).
22. Rüsch-Gerdes S, Pfyffer GE, Casal M et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-92.
23. Malik S, Willby M, Sikes D et al. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One 2012; 7: 1-10.
24. Pantel A, Petrella S, Matrat S et al. DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55: 4524-9.